
Post-Acquisition Kadian Timeline (2009-2020)

Kadian acquired	All in-person marketing stops	
• <u>FebAug. 2009</u>		
Materials submitted to FDA	• <u>Dec. 2013</u> All other marketing stops	Dec. 2020 Kadian Voluntarily
• <u>May 2009</u> In-person visits begin At start, 18 reps nationally	NO KADIAN MARKETING	Discontin
Only ever 1 or 2 reps in San Francisco	STOP	CCSF v Purdue Pharn 3:18-CV-7591 Allergan Defen Court Exhibit Admitted: 5/9/202

Norco Timeline






From 1996, when OxyContin was introduced to the market, to July 2002, Purdue has funded over 20,000 pain-related educational programs through direct sponsorship or financial grants. These grants included support for programs to provide physicians with opportunities to earn required continuing medical education credits, such as grand round presentations at hospitals and medical education seminars at state and local medical conferences. During 2001 and 2002, Purdue funded a series of nine programs throughout the country to educate hospital physicians and staff on how to comply with JCAHO's pain standards for hospitals and to discuss postoperative pain treatment. Purdue was one of only two drug companies that provided fund-

Continuing Seeding the Key Opinion **Clinical Decision** Medical Medical Leaders Support Tools Education Literature California **Opioid-Related** Front Groups **FSMB Joint Commission** Legislation


Continuing Medical Education

	Case 3:18-cv	v-07591-CRB Document 1281 Filed 04/25/22 Page 1 of 52		
1 2 3	City Attorney YVONNE R. Chief Deputy SARA J. EISE Chief of Com	U, State Bar # 189542 MERE, State Bar # 175394 Word Count: 15,541 City Attorney ENVERG, State Bar # 296303 pex & Affirmative Litigation		
4 5 6 7 8	OWEN J. C JAIME M. I JOHN H. G Deputy City Fox Plaza 1390 Marke San Francis(Telephone: jaime.huling	84. Defendants employed CME as part of the strategy to spread their message about		
⁹ ¹⁰ ¹⁰ ¹⁰ ¹⁰ ¹⁰ ¹⁰ ¹⁰ ¹⁰				
increase prescribing. Illustrative of the significance of the CME strategy, Endo budgeted not				
17 18 19	¹⁸ nall of its 2009 \$15.8 million Opana brand promotional budget for Promotional Speaker			
		Programs and reported its programs had a nearly 200% ROI. P-24561.		
23 24	v. PURDUE I			
25 26 27 28		Defendants. DECLARATION OF ANNA LEMBRE, M.D. 3:18-cv-07591-CRB		

Seeding The Medical Literature



Clinical Decision Support Tools



DAVID CHIU State Bar # 18954 City Attome YVONNE R. MERE, State Bar # 175394 Chief Deputy City Attorney SARA J. EISENBERG, State Bar # 296303 Chief of Complex & Affirmative Litigation EMENTS, State Bar # 141805 IAIME M HUI ING DÉLAYE State Bar # OHN H. GEORGE. State Bar # 29233 Deputy City Attomeys 1390 Market Street, Sixth Floor San Francisco, CA 94102 elephone: 415,554,3597 e.hulingdelaye@sfcityatty.org Attorneys for Plaintiff The People of the State California, acting by and through San Francis Attorney David Chiu 11 [Additional counsel appear on signature page 12 13 15 UNITED STATES NORTHERN DISTR SAN FRANC THE CITY AND COUNTY OF SAN FRANCISCO, CALIFORNIA and THE PEOPLE OF THE STATE OF CALIFOR Acting by and through San Francisco Cit Attomev DAVID CHIU 22 Plaintiff. 23 24 PURDUE PHARMA L.P., et al 25 Defendants. 26 27 28

Case 3:18-cv-07591-CRB Docume

89. **Professional Medical Societies and Patient Advocacy Groups:** An investigative report by the US Senate Finance Committee identified about \$65 million given by opioid manufacturers to professional groups such as the American Pain Society, the American Academy of Pain Medicine, and the Joint Commission Resources, to promote pain treatment practice guidelines that advocated unwarranted, expanded use of opioids. So-called "patient advocacy" groups were also funded by the opioid manufacturers. The Committee Report found that the amounts contributed suggest that "manufacturers view these organizations as helpful extensions" of their sales and marketing efforts." Significant funds were contributed by Teva (which led the way), along with Purdue, Janssen, Endo and Mallinckrodt. P-18565 00002, 9.

Federation Of State Medical Boards


	Case 3:18-cv-07591-CRB Document 1281 Fil	led 04/25/22 Page 1 of 52				
1 2 3 4 5 6 7 8	DAVID CHIU, State Bar # 189542 Gity Attorney YVONNE R. MERE, State Bar # 175394 Chief Deputy City Attorney SARA J EISENBERG, State Bar # 296303 Chief of Complex & Affirmative Lingation OWEN J. CLEMENTS, State Bar # 14805 JAIME M. HULING DELAYE, State Bar # 270784 JOHN H. GEORGE, State Bar # 292332 Deputy City Attorneys Fox Plaza 1390 Market Street, Sixth Floor San Francisco, CA 94102 Telephone: 415.554.3597 Taime hulingelasus/acficitanty.org	Word Count: 15,541				
9 10 11 12 13 14 15 16 17	⁹ ¹⁰ ¹⁰ ¹⁰ ¹⁰ ¹⁰ ¹⁰ ¹⁰ ¹⁰					
18 19 20 21 22 23 24 25 26	THE CITY AND COUNTY OF SAN FRANCISCO, CALIFORNIA and THE PEOPLE OF THE STATE OF CALIFORNIA, Acting by and through San Francisco City Attomey DAVID CHIU, Plaintiff, v. PURDUE PHARMA L.P., et al. Defendants.	Case No. 3:18-cv-07591-CRB Declaration of Anna Lembke, M.D. Judge: Honorable Charles R. Breyer				
27 28		DECLARATION OF ANNA LEMBRE, M.D. 3:18-cv-07591-CRB				

Joint Commission (JCAHO)

Case 3:18-cv-07591-CRB Document 1281 Filed 04/25/22 Page 1 of 52				
1 DAVID CHIU, State Bar # 189542 City Attorney YVONNE R. MERE, State Bar # 175394 2 YVONNE R. MERE, State Bar # 175394 3 SARA J. EISENBERG. State Bar # 296303				
Chief of Co JAME A I JOHN IG Deputy City Fox Plaza San Francis San Francis Telephone:				
Attorney To California, Attorney Da				
request from the US Senate Finance Committee stated that support for its "pain management				
activities" was provided by Purdue, Endo Pharmaceuticals, Ortho-McNeill, The National				
Pharmaceutical Council, Pfizer, and Abbott Labs, and that it had received almost \$4 million from				
organizations that made or promoted the use of opioid-based drugs.				
26 27 28 DECLARATION OF AINA LEMBRE, MD. 3.18-cv-07591-CRB				




Kadian Learning System





Kadian Sales Representative Depositions












Allergan Defendants Court Exhibit 00001.00016

Source: P-02983.00018; P-43013_00042; P-21431.00043



Allergan Defendants Court Exhibit 00001.00017

What Dr. Lembke Says:

 "Kadian does not have a ceiling or recommended maximal dose." P-02983_00007 (Sales representative training presentation slides).

What The Document Says:

Efficacy (con't)



- KADIAN[®] provides convenience and flexibility with once or twice a day dosing.
- KADIAN[®] doses can be titrated up every other day.
- KADIAN[®] does not have a ceiling or recommended maximal dose, especially in patients with chronic pain of malignancy. In such cases the total dose of KADIAN should be advanced until the desired therapeutic endpoint is reached or clinicallysignificant opioid-related adverse reactions intervene.
- KADIAN[®] has no significant food effect and can be administered without regard to meals for dosing convenience.
- KADIAN[®] is available as an extended release capsule, but it has 3 modes of administration

"Speaker Training" Presentation Slides

